ACET
Adicet Bio Inc
Adicet Bio Inc
$ACET Reports Strong Operational Highlights for Q1 2023, Progress in Allogenic Gamma Delta T-Cell Therapy Development Programs.
Adicet Bio, a clinical-stage biotech company, has reported financial results for Q1 2023 showing $231.6 million in cash, sufficient to fund its operating expenses until H1 2025. Operational highlights included progress in gamma delta T cell therapy development programs, a plan to submit an IND for ADI-925, and discussion with the FDA about a potential pivotal study for ADI-001. Although revenue and profits were not mentioned, Adicet Bio's progress is encouraging, and investors should watch for updates on regulatory discussions and plans for a potential pivotal study later this year.
4mo ago
$ACETAdicet Bio Inc
$ACET reports strong pipeline progress and financial results for Q4 2022
Adicet Bio has reported strong financial results for Q4 and the year ended December 31st, 2022. The clinical stage biotechnology company has made progress in advancing its gamma delta T cell therapy pipeline and clinical proof of concept. Adicet is enrolling patients for its ongoing trial for relapsed or refractory B-cell NHL and expects to submit an IND for ADI-925 in H2 2023. The company presented preclinical data for four new pipeline programs at SITC Annual Meeting last November, and its cash and cash equivalents securities are expected to be sufficient to fund its operating expenses into H1 2025.
6mo ago
$ACET